Xi'an Huitian Blood Products Co., Ltd. announced that it expects to receive not more than CNY 146.743 million in a round of funding on July 29, 2022. The transaction will include participation from new investor, Beijing Tiantan Biological Products Co., Ltd. Investor held the 21st meeting of the 8th board of directors and reviewed and approved the reorganization of the company. After the transaction Beijing Tiantan Biological Products Co., Ltd. will holds a total of 63.6962% equity.

The registered capital of the company is CNY 51 million. Investor will pay CNY 100 million within 10 working days after the completion of the industrial and commercial registration of the handover and capital increase as stipulated in the agreement, of which CNY 40.312631.270 million shall be included in the registered capital and CNY 59.687,368.730 million shall be included in the capital reserve.